Invitae | GenomeWeb


The first apps will be for individuals at low risk for inherited forms of cancer and heart disease, and will require a doctor's permission.

The national provider agreement is the latest in a series of deals related to reimbursement for the firm's genetic tests. 

CMS final pricing for a number of CPT codes brings positive news for various gene sequencing procedures and multi-analyte algorithm assays.

Researchers at Sharp Healthcare and Invitae uncovered a large deletion in RAD51D, a BRCA-interacting gene previously implicated in ovarian cancer risk.

The company reported $5.6 million in second quarter revenues, and announced it would launch a medical exome test by the first quarter of 2017.

Drug developers and genetic testing firms are contemplating how best to share variant classification data while protecting their commercial interests.

Following this approval, the firm said it now offers hereditary cancer, cardiology, and pediatric testing services in all 50 US states.

The company grew its test volume by 300 percent year over year, billing 9,700 reports and accessioning around 10,000 samples.

The new code is used for tests conducted by next-generation sequencing that include BRCA1, BRCA2, and 12 other genes even if they are part of multi-gene panels.

Invitae CEO Randy Scott tells Bloomberg that his company wants to be the 'Amazon of genetic testing.'


In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.